ArcticZymes Technologies — Regulatory Filings 2021

Dec 22, 2021

ArcticZymes Technologies launches new products and opens new production facility

ArcticZymes Technologies launches new products and opens new production facility

Tromsø, Norway, 22[nd] December 2021 - ArcticZymes Technologies ASA (OSE: AZT)

announces the launch of new products and opening of the new production facility

ArcticZymes technologies launches the following products:

· ArcticZymes R2D[TM] Ligase - Patent pending ligase with novel specificity

enabling the ligation of DNA to both ends of RNA using a DNA splint. The enzyme

is an enabling tool for new technology development and is expected to have broad

applicability in Molecular Diagnostics (MDx), Next Generation Sequencing (NGS),

and gene/RNA synthesis applications for potential therapeutic applications.

· IsoPol[®] BST[+] High Concentration Glycerol FREE - highly concentrated

formulation of the DNA polymerase to support ongoing customer opportunities for

utility in new NGS platform technologies and Point-of-Care diagnostic test

developments.

· M-SAN HQ ELISA kit - The new ELISA immunoassay product is an essential

support product for customers using the M-SAN HQ enzyme in biomanufacturing

processes for gene therapy and viral vaccine production. In combination with the

M-SAN HQ enzyme, the new immunoassay product provides a complete solution for

the critical elimination of DNA contamination during biomanufacturing.

· M-SAN HQ enzyme (Upscaled) - The upscaling of M-SAN HQ enzyme was timed to

coincide with the launch of the new ELISA kit. The M-SAN HQ enzyme manufacturing

process has been upscaled and transitioned to large-scale fermentation. This

successful upscaling achieved greater than a 100-fold increase in fermentation

yield. The upscaling was necessary to meet the expected increase in demand

following the launch of the ELISA kit and ensure customers can receive large

quantities of enzyme from a single production batch.

The ArcticZymes R2D[TM] Ligase and M-SAN HQ products will be available in our

warehouses during January 2022. The IsoPol[®] BST[+] High Concentration Glycerol

FREE product will be available during February 2022.

Furthermore, ArcticZymes Technologies is proud to announce the opening of its

new 500 m[2] production facility at the SIVA Innovation Centre in Tromsø. The

new state of the art facility caters for the scalable manufacturing of enzyme

products and meets the strict requirements demanded by ISO13485: In Vitro

Diagnostics (IVD) and cGMP. The facility has the capacity to support the

increasing production demands of existing products, future innovations, and

organic growth of the business over the next 4-5 years. Lastly all Tromsø based

employees are now located under one roof at the SIVA Innovation Centre.

ArcticZymes Technologies ASA, CEO, Jethro Holter said:

"It is a proud day for ArcticZymes Technologies and its employees to bring new

innovations to its customers.

We are delighted with the new production facilitates and inspired by the

prospect they will be instrumental in supporting future organic growth."

For more information, please contact:

ArcticZymes Technologies

CEO, Jethro Holter Tel: +47 46 85 91 46

CFO, Børge Sørvoll Tel: +47 95 29 01 87

ir@arcticzymes.com

About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the

development, manufacturing and commercialization of novel recombinant enzymes

for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics.

Listed on the Oslo Stock Exchange since 2005 originally under the [Biotec]

ticker, as Biotec Pharmacon. The company rebranded as ArcticZymes Technologies

in 2020 under the [AZT] ticker. Its headquarters are based in Tromsø, Norway, at

the SIVA Innovation Centre.

ArcticZymes Technologies' IP and capabilities are protected via a large

portfolio of patents.

For more information, please visit the website: www.arcticzymes.com.